Alexandra Stegemann

Twenty years of innovation, but a vision that remains unchanged. Valued for the standardized collection and analysis of tissue samples that has enabled a truly unique multi-omics database, we are on the verge of reshaping what is possible in the field of precision oncology. We have unlocked an understanding of the molecular reality of cancer at an unparalleled level that is now supporting biomarker and target discovery and validation, drug development, and clinical trial performance. We continue striving for a world where precision therapy is possible for each individual cancer patient. To learn more about our mission, visit www.indivumed-therapeutics.com.